Open Access
Cost-Effectiveness of Prophylactic Medications for the Treatment of Hereditary Angioedema Due to C1 Inhibitor Deficiency: A Real-World U.S. Perspective
Journal Of Managed Care And Specialty PharmacyPeer ReviewedBruce L. Zuraw2019Journals
No funding supported the writing of this commentary. The author reports personal fees from BioCryst, CSL Behring, Shire, and Pharming and grants from Ionis. He is chair of the US HAEA Medical Advisory Board and scientific advisor for HAE International.

The content you want is available to Zendy users.

Already have an account? Sign in
Having issues? Contact support